Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
Medicare Announces Timeline for Shifting from Volume to Value Based Reimbursement
By Kelly A. Briganti, JD, Editorial Director G2 Intelligence There has been much discussion about moving away from fee for service reimbursement and the need to tie reimbursement to the value provided, rather than the amount of care provided. That discussion takes...
The New 59 X(EPSU) Modifiers, X’d For Now
By Christopher P. Young, Editor, G2 Compliance Advisor The latest communication from the Centers for Medicare and Medicaid Services (CMS) concerning new modifiers, referred to as X(EPSU), intended to replace the 59 modifier, says that while the new modifiers are...
FDA Authorizes Marketing of 23andMe Direct-to-Consumer Genetic Screening Test
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence Only a little more than a year after receiving an FDA warning letter telling 23andMe to stop marketing its direct-to-consumer Personal Genome Service, the company finally has a bit of good news. The FDA...
Patient Test Requests Not Driving Health Care Costs
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Physicians' perceptions of the "demanding patient" may not be based in reality. According to a new study, published online Feb. 12 in JAMA Oncology, patients make demands for additional cancer...
LifeCode Obtains CAP Laboratory Accreditation Raises $20.5 Million
By Ron Shinkman, Editor, Laboratory Industry Report LifeCode, the California-based laboratory firm that focuses on next-generation sequencing assays, has obtained laboratory accreditation from the College of American Pathologists and raised $20.5 million from a...
Claritas Genomics Raises $15 Million to Expand Operations, Test Menu
By Stephanie Murg, Managing Director, G2 Intelligence Genetic diagnostic testing company Claritas Genomics (Cambridge, Mass.) has secured $15 million to fund expansion of its commercial operations and launch novel next generation sequencing-based tests for...
Human Longevity Licenses Assays, Platform from Personal Genome Diagnostics
By Ron Shinkman, Editor, Laboratory Industry Report Human Longevity, Inc., a California-based genomic laboratory, has entered into an agreement with Personal Genomic Diagnostics, Inc. to license the latter's products to expand its ability to analyze cancer genomes....
HHS Secretary Calls for Bi-Partisan Efforts to Improve Health Care
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence Health and Human Services Secretary Sylvia Matthews Burwell recently delivered a speech to the New America Foundation calling for Congress and the Administration to work together to capitalize on...
Medicare Fee-For-Service is Top of List for Fraud, Waste and Abuse
By Christopher P. Young, Editor, G2 Compliance Advisor Medicare fee-for-service (FFS) tops a list of 13 high error rate government programs estimated to have lost $106 billion during fiscal year 2013 to improper payments. According to the authors of a study by...
Obama Touts Precision Medicine Initiative in State of the Union
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies President Barack Obama announced a new precision medicine initiative this week in his State of the Union Address. Also known as personalized medicine, expanding the government's focus on...